CN111041025B - 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 - Google Patents
基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 Download PDFInfo
- Publication number
- CN111041025B CN111041025B CN201911300610.2A CN201911300610A CN111041025B CN 111041025 B CN111041025 B CN 111041025B CN 201911300610 A CN201911300610 A CN 201911300610A CN 111041025 B CN111041025 B CN 111041025B
- Authority
- CN
- China
- Prior art keywords
- sequence
- mrna
- gbd
- puromycin
- acetylgalactosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 90
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 title claims abstract description 88
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 title claims abstract description 56
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 50
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 49
- 230000008685 targeting Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 108091005804 Peptidases Proteins 0.000 claims abstract description 51
- 239000004365 Protease Substances 0.000 claims abstract description 51
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 51
- 229950010131 puromycin Drugs 0.000 claims abstract description 49
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 24
- 230000007017 scission Effects 0.000 claims abstract description 23
- 230000009471 action Effects 0.000 claims abstract description 20
- 239000012634 fragment Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000013600 plasmid vector Substances 0.000 claims abstract description 9
- 102000004357 Transferases Human genes 0.000 claims abstract description 8
- 108090000992 Transferases Proteins 0.000 claims abstract description 8
- 102000003960 Ligases Human genes 0.000 claims abstract description 7
- 108090000364 Ligases Proteins 0.000 claims abstract description 7
- 108700026220 vif Genes Proteins 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 108020004414 DNA Proteins 0.000 claims description 38
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 32
- 238000010008 shearing Methods 0.000 claims description 25
- 238000000338 in vitro Methods 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 15
- 238000013518 transcription Methods 0.000 claims description 15
- 230000035897 transcription Effects 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000013519 translation Methods 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 230000006337 proteolytic cleavage Effects 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000010367 cloning Methods 0.000 claims description 5
- 230000012202 endocytosis Effects 0.000 claims description 5
- 108020001775 protein parts Proteins 0.000 claims description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 108010032838 Sialoglycoproteins Proteins 0.000 claims description 3
- 102000007365 Sialoglycoproteins Human genes 0.000 claims description 3
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- 210000003494 hepatocyte Anatomy 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 102000006240 membrane receptors Human genes 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 abstract description 24
- 238000012377 drug delivery Methods 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 7
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000001647 drug administration Methods 0.000 abstract 1
- 230000007026 protein scission Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 description 19
- 238000010586 diagram Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 2
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 108010012058 leucyltyrosine Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Abstract
Description
Claims (4)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911300610.2A CN111041025B (zh) | 2019-12-17 | 2019-12-17 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
EP20902709.3A EP4019632A4 (en) | 2019-12-17 | 2020-12-14 | MRNA TARGET MOLECULE BASED ON N-ACETYLGALACTOSAMIN BINDING POLYPEPTIDE AND METHOD OF PRODUCTION THEREOF |
PCT/CN2020/136010 WO2021121173A1 (zh) | 2019-12-17 | 2020-12-14 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
AU2020405482A AU2020405482B2 (en) | 2019-12-17 | 2020-12-14 | mRNA targeting molecule based on N-acetylgalactosamine binding polypeptide and preparation method therefor |
JP2022536655A JP2023506635A (ja) | 2019-12-17 | 2020-12-14 | N-アセチルガラクトサミン結合ポリペプチドを含むmRNA標的化分子およびその調製方法 |
KR1020227023976A KR102616559B1 (ko) | 2019-12-17 | 2020-12-14 | N-아세틸갈락토사민 결합 폴리펩티드에 기초한 mRNA 표적 분자 및 이의 제조 방법 |
US17/693,173 US11759532B2 (en) | 2019-12-17 | 2022-03-11 | mRNA targeting molecule comprising N-acetylgalactosamine binding polypeptide and preparation method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911300610.2A CN111041025B (zh) | 2019-12-17 | 2019-12-17 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111041025A CN111041025A (zh) | 2020-04-21 |
CN111041025B true CN111041025B (zh) | 2021-06-18 |
Family
ID=70236828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911300610.2A Active CN111041025B (zh) | 2019-12-17 | 2019-12-17 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11759532B2 (zh) |
EP (1) | EP4019632A4 (zh) |
JP (1) | JP2023506635A (zh) |
KR (1) | KR102616559B1 (zh) |
CN (1) | CN111041025B (zh) |
AU (1) | AU2020405482B2 (zh) |
WO (1) | WO2021121173A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
CN111744019B (zh) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
CN113355381A (zh) * | 2020-08-20 | 2021-09-07 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5′帽子类似物及其制备方法和应用 |
CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101558081A (zh) * | 2006-12-11 | 2009-10-14 | 伯拉考成像股份公司 | 用于诊断和治疗应用的纤维蛋白结合肽缀合体 |
CN103547272A (zh) * | 2010-12-17 | 2014-01-29 | 箭头研究公司 | 基于肽的体内siRNA递送系统 |
CN107530436A (zh) * | 2015-01-21 | 2018-01-02 | 菲泽尔克斯公司 | 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统 |
CN108271387A (zh) * | 2015-08-07 | 2018-07-10 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
WO2019063843A1 (en) * | 2017-09-29 | 2019-04-04 | Nlife Therapeutics, S.L. | COMPOSITIONS AND METHODS FOR RELEASE OF MRNA IN HEPATIC CELLS |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
CN1297907A (zh) * | 1999-11-24 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人乙酰半乳糖苷转移酶45和编码这种多肽的多核苷酸 |
CN1347903A (zh) * | 2000-10-11 | 2002-05-08 | 上海博德基因开发有限公司 | 一种新的多肽——人GalNAc-T9.02和编码这种多肽的多核苷酸 |
AP2005003234A0 (en) | 2002-08-20 | 2005-03-31 | Genitrix Llc | Lectin compositions and methods for modulating an immune response to an antigen. |
EP2046375B1 (en) | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Methods and compositions for the selective activation of protoxins through combinatorial targeting |
AU2008333811B2 (en) | 2007-12-04 | 2014-05-01 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US20110124520A1 (en) | 2008-05-30 | 2011-05-26 | Massachuesetts Institute Of Technology | Compositions and Methods for Spatial Separation and Screening of Cells |
RU2013117288A (ru) | 2010-12-17 | 2015-01-27 | Эрроухэд Рисерч Корпорейшн | СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА |
RU2582235C2 (ru) | 2010-12-29 | 2016-04-20 | Ф.Хоффманн-Ля Рош Аг | Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот |
US8916696B2 (en) | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
JP2015518705A (ja) | 2012-04-02 | 2015-07-06 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
CN114015692A (zh) | 2013-03-14 | 2022-02-08 | 阿尔尼拉姆医药品有限公司 | 补体组分C5 iRNA组合物及其使用方法 |
BR112015022507A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
NZ631512A (en) | 2013-05-01 | 2016-10-28 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating apolipoprotein (a) expression |
JP6649248B2 (ja) | 2013-05-01 | 2020-02-19 | レグルス セラピューティクス インコーポレイテッド | 細胞取り込みの向上のための化合物および方法 |
WO2015023975A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating rna |
JP6754997B2 (ja) | 2013-08-26 | 2020-09-16 | 国立大学法人 東京大学 | 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法 |
WO2015107115A1 (en) | 2014-01-15 | 2015-07-23 | Basf Se | Saccharide-modified nucleic acid molecules |
CN104189897A (zh) | 2014-05-21 | 2014-12-10 | 深圳先进技术研究院 | 一种树突状细胞高效负载抗原的制备方法 |
US20170327524A1 (en) | 2014-10-10 | 2017-11-16 | Hoffmann-La Roche, Inc. | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
MX2017016088A (es) | 2015-06-15 | 2018-04-11 | Mpeg La Llc | Oligonucleotidos multi-conjugados definidos. |
KR20180039726A (ko) | 2015-09-04 | 2018-04-18 | 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 | 인슐린 면역글로불린 융합 단백질 |
CA3011469A1 (en) * | 2016-01-15 | 2017-07-20 | Galen Biotechnologies, Llc | Transfer rna ligand adduct libraries |
MA45478A (fr) | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
KR20190029576A (ko) | 2016-06-09 | 2019-03-20 | 큐어백 아게 | 핵산 카고용 하이브리드 담체 |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
EP3574102A4 (en) * | 2017-01-26 | 2020-09-30 | The Regents of The University of California | TARGETED GENE METHYLATION IN PLANTS |
CN110392577A (zh) | 2017-03-17 | 2019-10-29 | 库尔维科公司 | 用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂 |
CA3056756C (en) * | 2017-03-17 | 2021-12-07 | Cubicstars, Inc. | Method for producing complex of rna molecule and peptide, and utilization thereof |
MX2020003995A (es) | 2017-10-19 | 2020-07-22 | Curevac Ag | Nuevas moleculas de acido nucleico artificiales. |
CA3111836A1 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders |
WO2020086885A2 (en) * | 2018-10-24 | 2020-04-30 | Brandeis University | Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family pgt128 |
CN113226332A (zh) | 2018-11-02 | 2021-08-06 | 阿布特斯生物制药公司 | 二价靶向缀合物 |
CN114555621A (zh) | 2019-08-15 | 2022-05-27 | Ionis制药公司 | 键修饰的寡聚化合物及其用途 |
CN111041025B (zh) * | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
CN112111524B (zh) | 2020-01-10 | 2024-02-27 | 深圳瑞吉生物科技有限公司 | mRNA-GalNAc靶向分子的制备方法及其体内递送系统和应用 |
CN111744019B (zh) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
-
2019
- 2019-12-17 CN CN201911300610.2A patent/CN111041025B/zh active Active
-
2020
- 2020-12-14 JP JP2022536655A patent/JP2023506635A/ja active Pending
- 2020-12-14 AU AU2020405482A patent/AU2020405482B2/en active Active
- 2020-12-14 EP EP20902709.3A patent/EP4019632A4/en active Pending
- 2020-12-14 KR KR1020227023976A patent/KR102616559B1/ko active IP Right Grant
- 2020-12-14 WO PCT/CN2020/136010 patent/WO2021121173A1/zh unknown
-
2022
- 2022-03-11 US US17/693,173 patent/US11759532B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101558081A (zh) * | 2006-12-11 | 2009-10-14 | 伯拉考成像股份公司 | 用于诊断和治疗应用的纤维蛋白结合肽缀合体 |
CN103547272A (zh) * | 2010-12-17 | 2014-01-29 | 箭头研究公司 | 基于肽的体内siRNA递送系统 |
CN107530436A (zh) * | 2015-01-21 | 2018-01-02 | 菲泽尔克斯公司 | 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统 |
CN108271387A (zh) * | 2015-08-07 | 2018-07-10 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
WO2019063843A1 (en) * | 2017-09-29 | 2019-04-04 | Nlife Therapeutics, S.L. | COMPOSITIONS AND METHODS FOR RELEASE OF MRNA IN HEPATIC CELLS |
Also Published As
Publication number | Publication date |
---|---|
AU2020405482B2 (en) | 2023-04-20 |
KR102616559B1 (ko) | 2023-12-20 |
CN111041025A (zh) | 2020-04-21 |
KR20220106222A (ko) | 2022-07-28 |
EP4019632A1 (en) | 2022-06-29 |
US11759532B2 (en) | 2023-09-19 |
US20220265859A1 (en) | 2022-08-25 |
JP2023506635A (ja) | 2023-02-17 |
AU2020405482A1 (en) | 2022-04-07 |
EP4019632A4 (en) | 2022-11-02 |
WO2021121173A1 (zh) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111041025B (zh) | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 | |
US11634727B2 (en) | Recombinant nucleic acid molecule of transcriptional circular RNA and its application in protein expression | |
CA2304254C (en) | Trimerising module | |
EP1594973B1 (en) | Transposon-based targeting system | |
EP2351775B1 (en) | Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane translocation sequence and biologically active molecule and use thereof | |
JP2007135605A (ja) | 核酸構築物 | |
US8796431B2 (en) | Efficient production of peptides | |
US20090011995A1 (en) | Production of a soluble native form of recombinant protein by the signal sequence and secretional enhancer | |
KR20110128345A (ko) | 생물학적 활성 rna의 전달을 위한 조성물 및 방법 | |
JPS5863390A (ja) | Dna配列を微生物によつて発現する方法及びその生産物 | |
JP2024007554A5 (zh) | ||
NO177540B (no) | Fremgangsmåte for fremstilling av heterologe proteiner i Bombyx mori samt plasmid og rekombinant Bombyx mori nukleært polyhedrosevirus (BmNPV) | |
CN110408636B (zh) | 多重标签串联的dna序列及其在蛋白质表达纯化系统的应用 | |
EP1098987B1 (en) | Method for transformation of animal cells | |
KR20020071476A (ko) | 단백질 제조 방법 | |
EP1788082B1 (en) | Nucleic acid construct | |
JPWO2021178717A5 (zh) | ||
EP1639002B1 (en) | Cytokine variant polypeptides | |
CN114790225A (zh) | 一种新型内体逃逸肽及其应用 | |
CN114181315B (zh) | 一种内体逃逸肽及其应用 | |
WO2024041653A1 (zh) | 一种CRISPR-Cas13系统及其应用 | |
KR20220117091A (ko) | 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도 | |
CN117844806A (zh) | 一种5’-utr元件及其在提高蛋白表达量中的应用 | |
CN116515873A (zh) | LNP-mRNA递送系统在体内构建TAC-T细胞的设计和应用 | |
Rutter | PRODUCTION OF “VALUABLE” PROTEINS IN ALTERNATE BIOLOGICAL HOSTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Hu Yong Inventor after: Zhang Miaomiao Inventor before: Zhang Miaomiao |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 518057 floor 4, building 2, Shenzhen biological incubation base, No. 10, Gaoxin Zhongyi Road, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong Patentee after: Shenzhen Ruiji Biotechnology Co.,Ltd. Address before: 1435a, Hangdu building, 1006 Huafu Road, Huahang community, Huaqiang North Street, Futian District, Shenzhen City, Guangdong Province Patentee before: Shenzhen Ruiji Biotechnology Co.,Ltd. |